Dr Gupta on the Background of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma
Shilpa Gupta, MD, discusses the background of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.
Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape
Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma
A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.
Metastatic Urothelial Carcinoma: Intensifying Maintenance Immunotherapy
Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.
Real-World Data With Avelumab Maintenance Therapy in Metastatic Urothelial Carcinoma
Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.
Goals of Maintenance Therapy in Metastatic Urothelial Carcinoma
A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.
Metastatic Urothelial Carcinoma: Number of Frontline Chemotherapy Cycles
A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.
Dr Gupta on First-line Avelumab Maintenance in Advanced Urothelial Carcinoma
Shilpa Gupta, MD, discusses findings from a long-term analysis of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.
First-Line Treatment Options for Patients With Metastatic Urothelial Carcinoma
Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.
Novel Treatment Strategies in Muscle Invasive Bladder Cancer
A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.
Clinical Trial Data With Perioperative Therapy in MIBC: Bladder BRIDGister
Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.
Clinical Trial Data With Perioperative Therapy in MIBC: HCRN GU 16-257
Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.
Clinical Trial Data With Perioperative Therapy in MIBC: The RETAIN BLADDER Study
Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.
Muscle-Invasive Bladder Cancer: Role of Minimal Residual Disease in Adjuvant Therapy
Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.
Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer
Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.
Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer
Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.
MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments
Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.
Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer
A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.
How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?
A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.
Overview of Practice Patterns in Urothelial Carcinoma
A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.
Dr. Gupta on the Investigation of Enfortumab Vedotin With or Without Additional Therapy in mUC
Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.
Dr. Gupta on Unmet Needs in Frontline Treatment of Metastatic Urothelial Cancer.
Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.
Dr. Gupta on the Investigation of Cabozantinib Plus Avelumab in Metastatic Urothelial Cancer
Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.
Dr. Gupta on the Results of the PARADIGM Study in Urothelial Cancer
Shilpa Gupta, MD, discusses the results of the PARADIGM study in locally advanced or metastatic urothelial cancer.
Dr. Gupta on the Methodologies of the PARADIGM Study in Urothelial Cancer
Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.
Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer
Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.
Dr. Gupta on Developing Biomarkers of Lack of Response in Urothelial Carcinoma
Shilpa Gupta, MD, discusses the need to develop biomarkers of lack of response to immunotherapy in urothelial carcinoma.
Bright Future in Advanced Urothelial Cancer
Sequencing Considerations in mUC after Frontline IO
Metastatic Bladder Cancer: Progression After Maintenance
Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities
Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors
Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer
Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer
2 Clarke Drive Cranbury, NJ 08512